Mel-Mont Medical, a medical device and technology company dedicated to improving women’s health through the use of its patented DNA and mRNA collection assay kit, Mia by XytoTest®, has received clinical confirmation that it is as effective as samples taken by a physician.
Current estimates are that 569,847 women are diagnosed with cervical cancer each year and 311,365 women die from the disease. Cervical cancer is the third most common cancer among women worldwide, according to the Globocan HPV and Cancer Information Center.
The Mia by XytoTest® device is safe for women to use at home or in the doctor’s office without the need for a colposcope. The uniqueness of XytoTest® Mía gives sexually active women the opportunity to improve self-care and to test themselves for HPV-related cancers as a preventative measure. XytoTest®’s patented Mia technology enables laboratories to detect Hr-HPV-DNA and enables risk stratification by detecting mRNA E6/E7 biomarkers from the seven HPV types that have been shown to be most critical for the development of cervical cancer.
“The idea of self-monitoring with Mía by XytoTest® arose out of the need to raise awareness of self-care and the need for more accessible routine preventive testing in the sexually active female population. Molecular screening increases sensitivity and specificity and thus creates sensitivity and specificity and thus creates a uniqueness in the environment,” said Frank Melendez, CEO of Mel Monte Medical. Clinical added value in combating ridiculously high preventable morbidity and mortality, such as cervical cancer.”
A recent publication 1 compares clinician self-collected cervical samples for HPV infection with 14 HPV nucleic acid test and HPV mRNA E6/E7 test 7 and comes to the conclusion that Mia from XytoTest® is equal in The quality of the samples taken by the doctor.
“The application of accessible self-collected samples for CE-marked HPV mRNA testing has been approved under IVD Directive 98/97/EC, making PreTect and its E6/E7 mRNA technology a pioneer in this promising strategy,” said Benti. Mary Falange, global director of the laboratory division at PreTect, AS.
Women infected with HPV are not only given an efficient self-sampling option, but are also given appropriate treatment recommendations with their physicians, which are tailored to the mRNA biomarkers of the woman in question.
Mia by XytoTest®, 7-type mRNA E6/E7 for Women offers new and innovative alternatives in cervical cancer prevention and is now used throughout Europe and Mexico. The device also gives women in countries with poor health care or difficult economic conditions access to affordable and life-changing technology.
“Integrative, multidisciplinary molecular tests that accurately screen peeled cervical samples will improve cervical cancer prevention programs while simplifying medical procedures in HPV-infected women. Hence the concept of ‘liquid biopsy’ (i.e., ‘molecular’ cervical testing),” This is particularly important for the early detection of cervical cancer, which will be of critical importance in the coming years”, says Anna Gradissimo, Ph.D. from Albert Einstein College of Medicine, Bronx, New York, in recent paper (2).
About Millmont Medical:
Mel-Mont Medical, with offices in the United States and Europe, is a small medical device company initially focused on products that use mRNA to screen and diagnose HPV-related cancers in a minimally invasive manner.
Information about PreTect, AS:
PreTect AS, an ISO 13485:2016, CE/IVD certified and FDA approved mRNA manufacturing facility headquartered in Klokarstwa, Norway, is a wholly owned subsidiary of Mel-Mont Medical, Inc.
1 https://rdcu.be/clGVo
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904788/
for further information:
Daughter of Mary Falange
Ustadhagan 8 / N-3490
Klukarstwa, Norway
Phone: +47.32.79.88.00
Email: [email protected]
Web: www.mel-montmedical.com
Logo – https://mma.prnewswire.com/media/1588368/mel_mont_positivo_Logo.jpg
Original content by: Mel-Mont Medical, Inc. , transmitted by aktuell news
Original message: https://www.presseportal.de/pm/157684/4987019
